Episode
Inside Germany’s biotech capital infrastructure and innovation engine
- Podcast
- BioSpace
- Published
- May 21, 2026
- Duration seconds
- 1397
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/inside-germany-s-biotech-capital-infrastructure-and-innovation-engine/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/biospace-6696251/inside-germany-s-biotech-capital-infrastructure-and-innovation-engine.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of Denatured, as part of our series of the European life science investment ecosystem, you'll be hearing from Regina Hodits, managing director at Angelini Ventures and Sofia Ioannidou, VC partner at Andera Life Sciences. They examine Germany’s biotech and life sciences landscape, focusing on the scientific, infrastructure and policy shifts required to enable European companies to scale globally while remaining anchored in Europe. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Regina Hodits , Managing Director, Angelini Ventures Sofia Ioannidou , VC Partner, Andera Life Sciences Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.